Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (9499)	11/17/2003 7:24:19 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 52153

<<Nor can I understand why a retinal specialist would choose to offer the higher risk approach when there's no improvement in efficacy.>> We do not know that! High % for placebo (55%) screwed up Aptamer results. Combination of the A + V did generate additional efficacy, relative to each treatment alone. But as you said side effects rate increase does not generate any confidence here. Also, fact that Novartis did license DNA Avastin suggest that there is need for new drugs, and combination is one option. Miljenko